NNVC - NanoViricides Inc. Year-over-year net earnings per share growth for the last 12 months

Corporate emblem and logo of NanoViricides Corp (NNVC)

The absence of current sales due to the pre-commercial status of NanoViricides, Inc. (NNVC) shifts profit expectations to the post-certification stage of its drugs. The quarterly EPS trend demonstrates volatility, where the value of 21.70 reflects the metric's balance. The development of treatments against herpes and influenza in collaboration with global centers faces serious threats: capital shortages, delisting risks, and uncertainty regarding the effectiveness of nanotechnologies.

NanoViricides (NNVC) Year-over-year net earnings per share change for the last twelve months: for the period 07/04/2022 - 11/14/2026

NNVC (NanoViricides, Inc.): analytical breakdowns and indicator data

- market value and analyst target forecast:
Price Chart nanoviricides.com|NNVC - Fair Value Consensus
- market capitalization statistics:
Market Valuation NanoViricides Corp|NNVC - Enterprise Value
- book capitalization indicators:
Net Assets per Single Share NanoViricides|NNVC - Book Valuation of Business|Market Value to Book Value Ratio nanoviricides.com|NNVC - Total Business Assets
- debt and liquidity data:
Total Debt to Capital NanoViricides, Inc.|NNVC - Long-Term Debt to Capital|Short-Term Debt to Equity nanoviricides.com|NNVC - Company Aggregate Debt|Debt to Book Capitalization Ratio NanoViricides Corp|NNVC - Long-Term Debt|Company Current Liabilities NanoViricides|Quick Ratio nanoviricides.com
- earnings and market multiples details:
NNVC - Net Financial Result|Expected Profit NanoViricides, Inc.|NNVC - Company Value to Net Income|Forward P/E Multiple nanoviricides.com|NNVC - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple NanoViricides Corp|NNVC - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) NanoViricides|NNVC - Net earnings per share for the last four quarters|Quarterly EPS earnings growth nanoviricides.com|NNVC - Earnings per share growth this year|Earnings growth forecast for next year NanoViricides, Inc.
- sales and revenue data:
NNVC - Company Total Revenue|Company Projected Revenue nanoviricides.com|NNVC - Price-to-Revenue Coefficient|Forward Price-to-Revenue Multiple NanoViricides Corp
Summary company analysis:NanoViricides, Inc.
Flagship merchandise of nanoviricides.com

NanoViricides, Inc. (NNVC) is developing revolutionary nanotechnologies to neutralize viruses by creating barriers that mimic living cells to prevent pandemics. The percentage change in earnings per share compared to the previous quarter reflects the monetization efficiency of these innovations; meanwhile, the quarterly EPS trend reveals hidden margin degradation or potential profitability growth, signaling the real state of the business's fundamental value to the investor.

Analysis of competing companies

Gilead Sciences (GILD) - Year-over-year earnings per share growth for the last twelve months|Cidara Corp - Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months NVAX|Quarterly EPS earnings growth CureVac Pharma|Year-over-year earnings per share growth for the last twelve months Valneva SE (VALN)|Year-over-year net earnings per share change for the last twelve months vir.bio|Year-over-year earnings per share growth for the last twelve months SIGA Technologies SIGA|EBS: Year-over-year earnings per share growth for the last 12 months|Atea Pharmaceuticals Inc - Quarterly EPS earnings growth|IVVD - Quarterly EPS earnings growth|Enanta Pharmaceuticals (ENTA) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last 12 months INO|Year-over-year earnings per share growth for the last twelve months HilleVax|Earnings per share growth in annualized terms for the last twelve months Kalaris Therapeutics Inc. KLRS|Year-over-year net earnings per share growth for the last 12 months DYAI (Dyadic International)|Year-over-year earnings per share growth for the last twelve months TLPH (Talphera Corporation)|Quarterly EPS earnings growth COCP (Cocrystal Pharma, Inc.)|Year-over-year net earnings per share change for the last twelve months Traws Pharma Inc (TRAW)|DWTX - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per one share growth for the last 12 months QLGN (Qualigen Therapeutics Inc)|ALVR: Quarterly EPS earnings growth|VBIV - Year-over-year net earnings per share change for the last twelve months|VIRI (Virios Therapeutics Inc.) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Vaxart Corp (VXRT)